Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.004
Neutral
RSI(14)
53.782
Neutral
STOCH(KDJ)(9,3,3)
71.119
Buy
ATR(14)
4.251
Low Volatility
CCI(14)
26.097
Neutral
Williams %R
48.796
Neutral
TRIX(12,20)
0.040
Sell
StochRSI(14)
100.000
Buy
AbbVie Inc
ABBVView Detailed Chart
190.255USD
-0.965-0.50%
Market hours （ET）Quotes delayed by 15 min
336.05BMarket Cap
80.88P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.50%
5 Days
+1.68%
1 Month
+4.36%
6 Months
+8.56%
Year to Date
+7.07%
1 Year
+4.57%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
28
analysts
BUY
Current Rating
211.694
Target Price
12.29%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
172
Total
5
Median
8
Average
Company name
Ratings
Analysts
AbbVie Inc
ABBV
28
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Amgen Inc
AMGN
33
Alnylam Pharmaceuticals Inc
ALNY
33
Gilead Sciences Inc
GILD
30
1
2
3
...
35
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Buy
Moving Average
Indicators
Value
Direction
MA5
190.280
Sell
MA10
189.460
Buy
MA20
189.900
Buy
MA50
187.796
Buy
MA100
191.032
Sell
MA200
187.907
Buy
News
Berenberg raises AbbVie PT on higher immunology drug sales
** Berenberg raises PT on drugmaker AbbVie ABBV.N to $195 from $165, citing higher immunology drug sales ** New PT is a 8.7% downside to stock's last close** Brokerage says AbbVie knows the autoimmune market well ** Says co reduced exposure to antirheumatic drug Humira and bolstered cash flows t...
ReutersWed, Mar 12
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
Feb 7 (Reuters) - AbbVie ABBV.N said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria.AbbVie and co-developer Pfizer's PFE.N drug, Emblaveo, is approved in combination with an...
ReutersFri, Feb 7
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Ticker SymbolABBV
CompanyAbbVie Inc
CEOMr. Robert A. Michael, CPA
Websitehttps://www.abbvie.com/
Related Instruments
+0.32%
+0.07%
+3.00%
-0.18%
+0.01%
-6.60%
-0.51%
+0.27%
-0.72%
-0.39%
+0.64%
-0.58%
-0.00%
-1.17%
+3.57%
-0.41%
+0.38%
+3.69%
+0.23%
-2.97%
